Mylan Announces Final FDA Approval For Finasteride Tablets USP, 5mg
Main Category: Men's healthAlso Included In: Prostate / Prostate Cancer
Article Date: 20 Dec 2006 - 0:00 PDT
|
|
| Patient / Public: | ![]() |
5 (1 votes) |
| Health Professional: | ![]() |
5 (1 votes) |
| Article Opinions: | 0 posts |
Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Finasteride Tablets USP, 5mg.
The Mylan brand of Finasteride Tablets, a generic version of Merck's Proscar(R) Tablets, is approved for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms and reduce the risk of the need for surgery including transurethral resection of the prostate and prostatectomy. Total U.S. sales for the 5mg strength of Finasteride Tablets was approximately $553 million for the 12-month period ended Sept. 30, 2006, according to data from IMS Health.
This product will be shipped immediately.
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.
For more information about Mylan, please visit http://www.mylan.com.
Mylan Laboratories Inc.
http://www.mylan.com
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2010 MediLexicon International Ltd |


